EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

A Prescribed Digital Health App and Number of Migraine Days

Eine verschriebene digitale Gesundheits-App und die Zahl der Migränetage

Daniel Pach, Stefanie Lysk, Priska Heinz, Ulrike Held, Elif Huber, Simon Scholler, Markus A Dahlem, Martin Lysk, Jürgen Barth, Katja Icke, Claudia M Witt

JAMA Network Open · 01.07.2025 · 8 (7) · e2517708

DOI: 10.1001/jamanetworkopen.2025.17708 ↗

Auf einen Blick

In einer randomisierten Studie in Deutschland senkte die verschriebene Migräne-App die Zahl der Migränetage nach 12 Wochen nicht stärker als eine Kontroll-App. Es gab keine schweren unerwünschten Reaktionen.

Fragestellung

Vergleicht die verschreibbare digitale Gesundheits-App mit einer Kontroll-App die Zahl der Migränetage bei Erwachsenen mit Migräne?

Methode

2-armige, parallele, randomisierte klinische Studie, ferngesteuert in Deutschland von März bis Dezember 2021; Auswertung nach Intention-to-treat.

Ergebnisse

476 Teilnehmende in der Intention-to-treat-Population. Migränetage/28 Tage: 5,79 (95 %-KI 5,02–6,57) vs. 5,41 (95 %-KI 4,63–6,19); Differenz 0,38 Tage (95 %-KI −0,32 bis 1,08; P = .29).

Schlussfolgerung der Autor:innen

Die verschriebene digitale Migräne-App war der Kontroll-App mit reiner Kopfschmerzdokumentation nicht überlegen.

Kernaussagen

  • Keine signifikante Differenz bei Migränetagen nach 12 Wochen
  • Differenz 0,38 Tage (95 %-KI −0,32 bis 1,08)
  • Keine schweren unerwünschten Reaktionen berichtet

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 01.07.2025. Verfasst von Daniel Pach und 10 weiteren Autor:innen. Beteiligte Einrichtung: Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Social Medicine, …. Hauptthemen laut MEDLINE: Migraine Disorders, Mobile Applications. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The digital therapeutics market is expanding rapidly, with growing patient adoption. In some countries, digital health applications are already prescribable, reshaping clinical practice.

Objective

To compare the effectiveness of the prescribable digital health app used in this study with a control app in reducing the number of migraine days among adults diagnosed with migraine. Design, Setting, and Participants This 2-arm, parallel-group randomized clinical trial was conducted remotely across Germany from March to December 2021. Adults (≥18 years of age) with episodic or chronic migraine were randomly assigned in a 1:1 ratio to the intervention (n = 238) using a prescribable digital health app, called M-sense Migräne, or to the control (n = 239) group. Data were analyzed from February to March 2022.

Intervention

The intervention group used the full version of the prescribable digital health app, while the control group used an app version limited to headache diary features. Main Outcomes and Measures The primary outcome was the number of migraine days per a 28-day month after 12 weeks of using the app (assessed weeks 9-12), analyzed using analysis of covariance adjusted for baseline migraine days and migraine type. Secondary outcomes included the number of headache days per month, quality of life (assessed with the 6-item Headache Impact Test), self-efficacy (assessed with the Headache Management Self-Efficacy Scale German Short Form), Headache-Attributed Lost Time in the previous 30 days (HALT-30), migraine-specific health literacy, and days with acute headache medication use.

Results

Of 477 randomized participants, 476 were included in the intention-to-treat population (intervention, n = 238; control, n = 238). The participants’ overall mean (SD) age was 35.2 (10.4) years, 429 were female (90.1%); and the mean (SD) migraine history was 17.42 (10.49) years. After 12 weeks, there was no significant difference in the number of migraine days per month between groups. Migraine days per month decreased from a mean (SD) of 7.74 (3.70) to an adjusted mean of 5.79 (95% CI, 5.02-6.57) in the intervention group and from a mean (SD) of 7.76 (3.69) to an adjusted mean of 5.41 (95% CI, 4.63-6.19) in the control group, with an estimated between-group difference of 0.38 days (95% CI, −0.32 to 1.08 days; P = .29). There were no group differences for most secondary outcomes. No serious adverse reactions were reported. Conclusions and Relevance In this randomized clinical trial, the prescribed digital migraine health app did not show superiority in reducing migraine days compared with a control app having only basic headache documentation features. This finding underscores the need for randomized clinical trials as a cornerstone of a robust evaluation framework, ensuring both treatment efficacy and patient safety in an expanding digital therapeutics market. Trial Registration German Clinical Trials Register (DRKS) identifier: DRKS00024174

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersMobile ApplicationsHumansFemaleMaleAdultMiddle AgedGermanyQuality of LifeTelemedicineDigital Health

Autor:innen und Institutionen

  • Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Social Medicine, Epidemiology and Health Economics, Berlin, Germany.
  • Newsenselab GmbH, Berlin, Germany.
  • Department of Biostatistics at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
  • Robert Koch Institute, Berlin, Germany.
  • Migraine Aura Foundation, Berlin, Germany.
  • Institute for Complementary and Integrative Medicine, University Hospital Zurich and University Zurich, Zurich, Switzerland.

Zitieren

APA

Pach, D., Lysk, S., Heinz, P., Held, U., Huber, E., Scholler, S., Dahlem, M. A., Lysk, M., Barth, J., Icke, K., & Witt, C. M. (2025). A Prescribed Digital Health App and Number of Migraine Days. JAMA Network Open, 8(7), e2517708. https://doi.org/10.1001/jamanetworkopen.2025.17708

Vancouver

Pach D, Lysk S, Heinz P, Held U, Huber E, Scholler S, et al. A Prescribed Digital Health App and Number of Migraine Days. JAMA Network Open. 2025;8(7):e2517708. doi:10.1001/jamanetworkopen.2025.17708

BibTeX
@article{Pach2025,
  author = {Pach, Daniel and Lysk, Stefanie and Heinz, Priska and Held, Ulrike and Huber, Elif and Scholler, Simon and Dahlem, Markus A and Lysk, Martin and Barth, Jürgen and Icke, Katja and Witt, Claudia M},
  title = {A Prescribed Digital Health App and Number of Migraine Days},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {7},
  pages = {e2517708},
  doi = {10.1001/jamanetworkopen.2025.17708}
}
Kostenlos starten →